| scholarly article | Q13442814 |
| P50 | author | Naveed Sattar | Q37378984 |
| Iain McInnes | Q41687181 | ||
| Christian Delles | Q43096626 | ||
| P2093 | author name string | Janet S Lee | |
| Jane E Salmon | |||
| Liz Thompson | |||
| Joan M Bathon | |||
| Jon T Giles | |||
| Christine E Codding | |||
| Andre D Beaulieu | |||
| Timothy H Carlson | |||
| P2860 | cites work | Elevated levels of small, low-density lipoprotein with high affinity for arterial matrix components in patients with rheumatoid arthritis: possible contribution of phospholipase A2 to this atherogenic profile | Q43837372 |
| Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. | Q44550492 | ||
| Overproduced interleukin 6 decreases blood lipid levels via upregulation of very-low-density lipoprotein receptor. | Q46015999 | ||
| Genetic variants associated with Lp(a) lipoprotein level and coronary disease. | Q50572117 | ||
| Interleukin-6 stimulates LDL receptor gene expression via activation of sterol-responsive and Sp1 binding elements. | Q52539964 | ||
| Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: A double-blind, placebo-controlled study | Q57232023 | ||
| Fibrin D-dimer and coronary heart disease: prospective study and meta-analysis | Q73881440 | ||
| Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-alpha therapy | Q80213278 | ||
| Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review | Q28755180 | ||
| Progress and challenges in translating the biology of atherosclerosis | Q29619982 | ||
| Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade: a prospective cohort study in ankylosing spondylitis. | Q33436848 | ||
| Are markers of inflammation more strongly associated with risk for fatal than for nonfatal vascular events? | Q33474334 | ||
| EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis | Q33505914 | ||
| Circulating inflammatory and hemostatic biomarkers are associated with risk of myocardial infarction and coronary death, but not angina pectoris, in older men. | Q33606548 | ||
| Expert consensus document on arterial stiffness: methodological issues and clinical applications | Q33999785 | ||
| Lipoprotein subclasses determined by nuclear magnetic resonance spectroscopy and coronary atherosclerosis in patients with rheumatoid arthritis | Q34037325 | ||
| Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis | Q34283776 | ||
| Interleukin-6 inhibition for treatment of rheumatoid arthritis: A review of tocilizumab therapy | Q34343286 | ||
| Changes in the concentration and composition of plasma lipoproteins during the acute phase response | Q34530914 | ||
| Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality | Q35737842 | ||
| Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host | Q35753611 | ||
| Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies | Q35863952 | ||
| The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis | Q35864053 | ||
| Small dense low-density lipoprotein and its role as an independent predictor of cardiovascular disease | Q36532721 | ||
| Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions | Q37415092 | ||
| Role for TNF in atherosclerosis? Lessons from autoimmune disease | Q37472928 | ||
| IL-6: from its discovery to clinical applications | Q37735571 | ||
| Atherogenic effects of TNF-α and IL-6 via up-regulation of scavenger receptors | Q39375911 | ||
| Fibrinolytic activation markers predict myocardial infarction in the elderly. The Cardiovascular Health Study | Q40821822 | ||
| HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis | Q42610707 | ||
| Tocilizumab monotherapy reduces arterial stiffness as effectively as etanercept or adalimumab monotherapy in rheumatoid arthritis: an open-label randomized controlled trial | Q42611547 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| placebo | Q269829 | ||
| P304 | page(s) | 694-702 | |
| P577 | publication date | 2013-12-24 | |
| P1433 | published in | Annals of the Rheumatic Diseases | Q4767876 |
| P1476 | title | Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study | |
| P478 | volume | 74 |
| Q64355353 | Association of Interleukin 6 Receptor Variant With Cardiovascular Disease Effects of Interleukin 6 Receptor Blocking Therapy: A Phenome-Wide Association Study |
| Q92104941 | Autoimmunity and Inflammation Link to Cardiovascular Disease Risk in Rheumatoid Arthritis |
| Q36195284 | Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA). |
| Q30234528 | Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis. |
| Q30235341 | Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis. |
| Q24185797 | Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis |
| Q91776881 | Cardiometabolic comorbidities in RA and PsA: lessons learned and future directions |
| Q27008927 | Cardiorheumatology: cardiac involvement in systemic rheumatic disease |
| Q33582869 | Cardiovascular Comorbidity in Inflammatory Rheumatological Conditions. |
| Q95277553 | Cardiovascular Impairment in COVID-19: Learning From Current Options for Cardiovascular Anti-Inflammatory Therapy |
| Q88917533 | Cardiovascular Safety of Biologics and JAK Inhibitors in Patients with Rheumatoid Arthritis |
| Q38950371 | Cardiovascular disease in patients with rheumatoid arthritis |
| Q38260198 | Cardiovascular risk and the use of biologic agents in rheumatoid arthritis |
| Q99240510 | Cardiovascular risk in inflammatory arthritis: rheumatoid arthritis and gout |
| Q34563216 | Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment |
| Q92340149 | Cardiovascular safety of tocilizumab: A systematic review and network meta-analysis |
| Q92628084 | Comparative effect of tumour necrosis factor inhibitors versus other biological agents on cardiovascular risk-associated biomarkers in patients with rheumatoid arthritis |
| Q92006099 | Comparison of PREDICTS atherosclerosis biomarker changes after initiation of new treatments in patients with SLE |
| Q37282484 | Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis |
| Q33725505 | Concomitant Use of Statins in Tocilizumab-Treated Patients with Rheumatoid Arthritis: A Post Hoc Analysis |
| Q38741861 | Current and future therapies for addressing the effects of inflammation on HDL cholesterol metabolism |
| Q26830297 | Current therapies for lowering lipoprotein (a) |
| Q38666239 | Cytokines in rheumatoid arthritis - shaping the immunological landscape |
| Q41200262 | Dextromethorphan Exhibits Anti-inflammatory and Immunomodulatory Effects in a Murine Model of Collagen-Induced Arthritis and in Human Rheumatoid Arthritis |
| Q102059107 | Diabesity: the combined burden of obesity and diabetes on heart disease and the role of imaging |
| Q36123376 | Differences in GlycA and lipoprotein particle parameters may help distinguish acute kawasaki disease from other febrile illnesses in children |
| Q35753510 | Differential regulation of Th17 and T regulatory cell differentiation by aryl hydrocarbon receptor dependent xenobiotic response element dependent and independent pathways |
| Q37637193 | Does a lack of physical activity explain the rheumatoid arthritis lipid profile? |
| Q38386565 | Effect of IL-6 receptor blockade on high-sensitivity troponin T and NT-proBNP in rheumatoid arthritis |
| Q44067316 | Effects of Baricitinib on Lipid, Apolipoprotein, and Lipoprotein Particle Profiles in a Phase IIb Study of Patients With Active Rheumatoid Arthritis |
| Q26748085 | Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist |
| Q54943957 | Effects of tumor necrosis factor inhibitors and tocilizumab on the glycosylated hemoglobin levels in patients with rheumatoid arthritis; an observational study. |
| Q40169515 | Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK-1 Inhibitor, After Short-Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials |
| Q35580177 | Emerging translational approaches to target STAT3 signalling and its impact on vascular disease |
| Q26770209 | From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To Identify Novel Targets for Atheroprotection |
| Q38724634 | High-density lipoprotein and inflammation in cardiovascular disease |
| Q38241232 | IL-6 biology: implications for clinical targeting in rheumatic disease |
| Q35536380 | IL-6 blockade by monoclonal antibodies inhibits apolipoprotein (a) expression and lipoprotein (a) synthesis in humans |
| Q35859326 | IL-6 trans-signaling increases expression of airways disease genes in airway smooth muscle |
| Q90389973 | Identifying the anti-inflammatory response to lipid lowering therapy: a position paper from the working group on atherosclerosis and vascular biology of the European Society of Cardiology |
| Q92122504 | Immunotherapy for the rheumatoid arthritis-associated coronary artery disease: promise and future |
| Q38293477 | Impact of systemic inflammation and autoimmune diseases on apoA-I and HDL plasma levels and functions |
| Q41914520 | Improvement of High-Density Lipoprotein Function in Patients With Early Rheumatoid Arthritis Treated With Methotrexate Monotherapy or Combination Therapies in a Randomized Controlled Trial |
| Q31137082 | Incidence of Gastrointestinal Perforations in Patients with Rheumatoid Arthritis Treated with Tocilizumab from Clinical Trial, Postmarketing, and Real-World Data Sources |
| Q52312175 | Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications. |
| Q54049063 | Increased thrombin generation in a mouse model of cancer cachexia is partially interleukin-6 dependent. |
| Q56337838 | Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty |
| Q38287565 | Inflammation, adiposity, and atherogenic dyslipidemia in rheumatoid arthritis: is there a paradoxical relationship? |
| Q92368368 | Inflammation, Frailty and Cardiovascular Disease |
| Q41103987 | Interleukin 6 Inhibition and Coronary Artery Disease in a High-Risk Population: A Prospective Community-Based Clinical Study |
| Q37469175 | Interleukin 6 regulates psoriasiform inflammation-associated thrombosis. |
| Q39573881 | Interleukins 6 and 8 and abdominal fat depots are distinct correlates of lipid moieties in healthy pre- and postmenopausal women |
| Q88046104 | Interrelated reduction of chemerin and plasminogen activator inhibitor-1 serum levels in rheumatoid arthritis after interleukin-6 receptor blockade |
| Q26746659 | Is the risk of cardiovascular disease altered with anti-inflammatory therapies? Insights from rheumatoid arthritis |
| Q38554197 | Lipid and Metabolic Changes in Rheumatoid Arthritis. |
| Q49792187 | Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies |
| Q58567872 | Lipids and Atherogenic Indices Fluctuation in Rheumatoid Arthritis Patients on Long-Term Tocilizumab Treatment |
| Q42369530 | Lipoprotein cholesterol fractions are related to markers of inflammation in children and adolescents with juvenile idiopathic arthritis: a cross sectional study. |
| Q39308941 | Lipoprotein(a): A Lipoprotein Whose Time Has Come |
| Q39368804 | Lipoprotein(a): A missing culprit in the management of athero-thrombosis? |
| Q27694518 | Managing cardiovascular risk in patients with inflammatory arthritis: practical considerations |
| Q38939820 | Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis. |
| Q26824970 | Monoclonal antibodies in rheumatoid arthritis: comparative effectiveness of tocilizumab with tumor necrosis factor inhibitors |
| Q38230699 | Pathogenesis and treatment of atherosclerosis in lupus |
| Q39371679 | Pathogenetic insights from the treatment of rheumatoid arthritis |
| Q49603124 | Potential of anti-inflammatory agents for treatment of atherosclerosis |
| Q35994802 | Preventing Heart Failure in Inflammatory and Immune Disorders |
| Q38745066 | Profile of sarilumab and its potential in the treatment of rheumatoid arthritis. |
| Q89748492 | Reflections on 'older' drugs: learning new lessons in rheumatology |
| Q58710440 | Research Progress on the Relationship between Atherosclerosis and Inflammation |
| Q46172380 | Review of Routine Laboratory Monitoring for Patients with Rheumatoid Arthritis Receiving Biologic or Nonbiologic DMARDs. |
| Q38794852 | Rheumatoid Arthritis Pharmacotherapies: Do They Have Anti-Atherosclerotic Activity? |
| Q92442225 | Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long-Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis |
| Q38665700 | Safety profile of biological therapies for treating rheumatoid arthritis |
| Q38393883 | Safety, tolerability, efficacy and pharmacodynamics of the selective JAK1 inhibitor GSK2586184 in patients with systemic lupus erythematosus |
| Q48088302 | Selective improvement of pulmonary arterial hypertension with a dual ETA/ETB receptors antagonist in the apolipoprotein E-/- model of PAH and atherosclerosis. |
| Q36430779 | Serum amyloid A impairs the antiinflammatory properties of HDL |
| Q35257568 | Significant effects of biologic therapy on lipid profiles and insulin resistance in patients with rheumatoid arthritis |
| Q28076558 | Spotlight on sirukumab for the treatment of rheumatoid arthritis: the evidence to date |
| Q38766654 | Systemic Inflammation and Arrhythmogenesis: A Review of Mechanistic and Clinical Perspectives |
| Q92241365 | Targeting Early Atherosclerosis: A Focus on Oxidative Stress and Inflammation |
| Q60959818 | Targeting Inflammation to Prevent Cardiovascular Disease in Chronic Rheumatic Diseases: Myth or Reality? |
| Q92885360 | Targeting Inflammation to Reduce Atherosclerotic Cardiovascular Risk in People With HIV Infection |
| Q38519523 | Targeting inflammation in the prevention of cardiovascular disease in patients with inflammatory arthritis. |
| Q38836998 | Targeting inflammation to reduce cardiovascular disease risk: a realistic clinical prospect? |
| Q50109832 | The Impact of Biologics and Tofacitinib on Cardiovascular Risk Factors and Outcomes in Patients with Rheumatic Disease: A Systematic Literature Review |
| Q35135726 | The association between reduction in inflammation and changes in lipoprotein levels and HDL cholesterol efflux capacity in rheumatoid arthritis |
| Q40772658 | The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo/active-controlled, d |
| Q98615013 | Tocilizumab improves oxidative stress and endothelial glycocalyx: A mechanism that may explain the effects of biological treatment on COVID-19 |
| Q36234050 | Tocilizumab improves the proatherothrombotic profile of rheumatoid arthritis patients modulating endothelial dysfunction, NETosis, and inflammation. |
| Q93196330 | Translating IL-6 biology into effective treatments |
| Q39215606 | Vascular inflammation and low-density lipoproteins: is cholesterol the link? A lesson from the clinical trials |
| Q58571133 | Venous Thrombosis and Post-Thrombotic Syndrome: From Novel Biomarkers to Biology |
| Q35118364 | What is the future of targeted therapy in rheumatology: biologics or small molecules? |
| Q90702746 | [Janus kinase inhibitors : State of the art in clinical use and future perspectives] |
Search more.